Literature DB >> 8099970

Effect of metadoxine on striatal dopamine levels in C57 black mice.

F Fornai1, M Grazia Alessandrì, U Bonuccelli, V Scalori, G U Corsini.   

Abstract

In the present study, we examined the effect of metadoxine on striatal levels of dopamine, 5-hydroxytryptamine (5-HT) and their metabolites in male C57 Black mice. Striatal content was assayed after systemic administration of metadoxine ranging from 1 micrograms kg-1 to 500 mg kg-1. Striatal dopamine increased 1 h after treatment with metadoxine (150 mg kg-1), but the most notable effect was obtained 24 h after the drug administration. At this time a plateau was reached; the two major metabolites of dopamine showed the same trend. Seven days after metadoxine administration, striatal dopamine approached the control values. Over the same time intervals, striatal 5-HT increased to a lesser extent and 5-hydroxy-indoleacetic acid did not differ significantly from controls. Striatal dopamine increased significantly at a dose of 250 micrograms kg-1 up to a dose of 1 mg kg-1 metadoxine; no further increment was observed between 1 and 500 mg kg-1 metadoxine. Administration of each component at doses equimolar to 1 mg metadoxine showed that pyridoxine produced only a mild increase in striatal dopamine compared with controls. We suggest that the metadoxine-induced striatal dopamine increase is obtained by increasing synthesis of dopamine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099970     DOI: 10.1111/j.2042-7158.1993.tb05579.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

Review 1.  Pharmacotherapy for Fragile X Syndrome: Progress to Date.

Authors:  Matthew H Davenport; Tori L Schaefer; Katherine J Friedmann; Sarah E Fitzpatrick; Craig A Erickson
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

2.  A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence.

Authors:  Irene Guerrini; Claudio Gentili; Gloria Nelli; Mario Guazzelli
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-12-18

Review 3.  Fragile X targeted pharmacotherapy: lessons learned and future directions.

Authors:  Craig A Erickson; Matthew H Davenport; Tori L Schaefer; Logan K Wink; Ernest V Pedapati; John A Sweeney; Sarah E Fitzpatrick; W Ted Brown; Dejan Budimirovic; Randi J Hagerman; David Hessl; Walter E Kaufmann; Elizabeth Berry-Kravis
Journal:  J Neurodev Disord       Date:  2017-06-12       Impact factor: 4.025

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.